CARGO Therapeutics (NASDAQ:CRGX - Free Report) had its price target increased by Jefferies Financial Group from $3.70 to $5.00 in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have a hold rating on the stock.
CARGO Therapeutics Stock Performance
Shares of NASDAQ CRGX traded down $0.03 during trading on Tuesday, reaching $4.58. The company had a trading volume of 907,690 shares, compared to its average volume of 702,420. CARGO Therapeutics has a 52 week low of $3.00 and a 52 week high of $25.45. The stock has a market cap of $210.95 million, a PE ratio of -0.99 and a beta of 0.28. The business's 50 day moving average price is $4.28 and its 200-day moving average price is $5.90.
Institutional Investors Weigh In On CARGO Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC raised its stake in shares of CARGO Therapeutics by 565.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,800 shares of the company's stock worth $84,000 after buying an additional 4,929 shares during the last quarter. Ascent Group LLC bought a new stake in shares of CARGO Therapeutics during the first quarter worth approximately $43,000. Brooklyn Investment Group raised its stake in shares of CARGO Therapeutics by 512.3% during the first quarter. Brooklyn Investment Group now owns 11,328 shares of the company's stock worth $46,000 after buying an additional 9,478 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of CARGO Therapeutics during the first quarter worth approximately $46,000. Finally, Invesco Ltd. bought a new stake in shares of CARGO Therapeutics during the fourth quarter worth approximately $165,000. 93.16% of the stock is owned by institutional investors.
CARGO Therapeutics Company Profile
(
Get Free Report)
CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.
Featured Stories
Before you consider CARGO Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CARGO Therapeutics wasn't on the list.
While CARGO Therapeutics currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
